No, Mounjaro is not a semaglutide. Mounjaro is the brand name for tirzepatide, a once-weekly subcutaneous injection from Eli Lilly that activates two incretin receptors: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). Semaglutide is a different molecule, made by Novo Nordisk, that activates only the GLP-1 receptor. It is sold under the brand names Ozempic and Rybelsus for type 2 diabetes and Wegovy for chronic weight management. The two drugs are in the same broad therapeutic family but are chemically and mechanistically distinct.
Mounjaro vs Semaglutide: The Key Differences
| Feature | Mounjaro (Tirzepatide) | Ozempic / Wegovy (Semaglutide) |
|---|---|---|
| Manufacturer | Eli Lilly | Novo Nordisk |
| Mechanism | Dual GIP and GLP-1 receptor agonist | GLP-1 receptor agonist only |
| Molecular Type | 39 amino acid peptide | 31 amino acid peptide |
| Frequency | Once weekly subcutaneous | Once weekly subcutaneous (Ozempic, Wegovy); daily oral (Rybelsus) |
| FDA-Approved Doses | 2.5, 5, 7.5, 10, 12.5, 15 mg | 0.25, 0.5, 1, 2 mg (Ozempic); up to 2.4 mg (Wegovy) |
| Diabetes Brand | Mounjaro | Ozempic, Rybelsus |
| Weight Management Brand | Zepbound | Wegovy |
What Tirzepatide Does That Semaglutide Does Not
Semaglutide is a single-receptor agonist; it binds and activates the GLP-1 receptor. Tirzepatide is a dual agonist; it binds and activates both the GLP-1 receptor and the GIP receptor. GIP is another incretin hormone released by the K-cells of the small intestine in response to food. GIP and GLP-1 work together in the natural state to enhance insulin secretion in a glucose-dependent way. By activating both receptors, tirzepatide produces additive effects on insulin secretion, appetite suppression, and gastric emptying. The dual mechanism is thought to drive the larger average weight loss observed with tirzepatide compared with GLP-1-only agents.
FDA-Approved Uses
Mounjaro
FDA-approved in May 2022 as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, per the Mounjaro prescribing information. Mounjaro is not FDA-approved for weight loss; the same active ingredient (tirzepatide) is sold as Zepbound for weight management and obstructive sleep apnea.
Ozempic
FDA-approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes, and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, per the Ozempic prescribing information. Maximum dose is 2 mg weekly.
Wegovy
FDA-approved for chronic weight management in adults with obesity (BMI 30 or higher) or overweight (BMI 27 or higher) with at least one weight-related comorbidity, in adolescents 12 years and older with obesity, and for cardiovascular risk reduction in adults with established cardiovascular disease and overweight or obesity. Maximum dose is 2.4 mg weekly.
Rybelsus
FDA-approved as an oral semaglutide tablet for adults with type 2 diabetes. Maximum dose is 14 mg daily, taken on an empty stomach with a small sip of water.
Head-to-Head: SURPASS-2
The SURPASS-2 trial, published in the New England Journal of Medicine, was a 40-week open-label trial in 1,879 adults with type 2 diabetes inadequately controlled on metformin. Participants received tirzepatide 5, 10, or 15 mg weekly, or semaglutide 1 mg weekly. At week 40, the mean reduction in A1C was 2.01, 2.24, and 2.30 percentage points for the three tirzepatide doses, compared with 1.86 for semaglutide. Mean weight loss was approximately 7.6, 9.3, and 11.2 kg for the tirzepatide doses, compared with 5.7 kg for semaglutide. SURPASS-2 used semaglutide 1 mg, which is the maximum Ozempic dose at the time of the trial; current Ozempic includes a 2 mg dose, and Wegovy goes up to 2.4 mg, so direct comparisons to maximum-dose semaglutide remain uncertain in head-to-head randomized data.
Shared Side Effects and Safety Warnings
Both drug classes share a similar adverse event profile because they both activate the GLP-1 receptor. Common reactions include nausea, diarrhea, vomiting, constipation, abdominal pain, decreased appetite, and injection-site reactions. Less common but serious risks include pancreatitis, gallbladder disease, acute kidney injury from dehydration, severe hypersensitivity, hypoglycemia in patients also taking insulin or sulfonylureas, and diabetic retinopathy complications. Both labels carry a boxed warning regarding thyroid C-cell tumors observed in rodent studies. Both are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
Cost, Coverage, and Access
Both drug families face high list prices (often more than $1,000 per month at retail) and inconsistent insurance coverage outside of the diabetes indications. Manufacturer savings cards (Lilly Cares, NovoCare) reduce out-of-pocket cost for eligible commercially insured patients but exclude federal program beneficiaries. During the 2022 to 2024 shortage, compounded versions were widely available; both shortages have since been declared resolved by the FDA, narrowing the legal basis for routine compounding.
Choosing Between Them
- If your indication is type 2 diabetes, Ozempic, Mounjaro, and Rybelsus are all reasonable starting points. Coverage and prior-authorization rules often drive selection.
- If your indication is chronic weight management, the choice is between Wegovy (semaglutide) and Zepbound (tirzepatide). Indirect comparisons favor tirzepatide for magnitude of weight loss.
- If you have prediabetes or elevated A1C and your clinician is considering preventive therapy, see our treatment hub and our overview of A1C levels.
- Switching between agents requires retitration and clinician oversight; do not change drugs on your own.
The Bottom Line
Mounjaro is not a semaglutide. Mounjaro is tirzepatide, a dual GIP and GLP-1 receptor agonist; semaglutide is a GLP-1-only agonist sold as Ozempic, Rybelsus, and Wegovy. The two drug families share much of the same safety profile but differ in mechanism and in the magnitude of weight loss observed in clinical trials. Selection depends on your indication, your insurance, your tolerability, and your prescriber’s clinical judgment.
Medical disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting, stopping, or changing any medication or treatment plan.
